Kura Oncology (KURA) Gains Momentum as Barclays Sees Significant Potential in Ziftomenib Approval

Kura Oncology Inc. (NASDAQ:KURA) is one of the stocks that will double in 2026. On November 24, Barclays analyst Etzer Darout raised the firm’s price target on Kura Oncology to $28 from $11 and maintained an Overweight rating on the shares. This decision was made as Barclays saw potential in the company’s ziftomenib approval.

This approval came earlier, on November 18, when Kura Oncology and Kyowa Kirin Co. Ltd. announced that the US FDA granted full approval to KOMZIFTI (ziftomenib) for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia/AML harboring a susceptible NPM1 mutation who lack satisfactory alternative treatment options. KOMZIFTI is the first and only once-daily, oral menin inhibitor approved for this devastating blood cancer, which affects ~30% of AML cases and often leads to early relapse.

Kura Oncology is prepared to launch the new medicine immediately. The approval is supported by data from the pivotal KOMET-001 trial, which evaluated KOMZIFTI in 112 R/R NPM1-mutated AML patients. The trial demonstrated compelling efficacy, with a combined rate of complete remission/CR plus CR with partial hematologic recovery/CRh of 21.4%. A key advantage highlighted by the data is KOMZIFTI’s favorable safety profile: it was approved with no Boxed Warning related to QTc prolongation or Torsades de Pointes, easing co-administration with other medications. The most common adverse reactions included various lab abnormalities (e.g., increased AST/ALT, decreased potassium, decreased albumin) and infections.

Kura Oncology Inc. (NASDAQ:KURA) is a clinical-stage biopharmaceutical company that develops medicines for the treatment of cancer.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.